Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Diarrhea
Oral antineoplastic agent
Safety
Side effect
Toxicity
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
10
2020
accepted:
19
01
2021
pubmed:
29
1
2021
medline:
24
7
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Diarrhea is one of the most frequent class adverse events associated with targeted oral antineoplastic agents (OAAs). Our objective was to analyze the incidence, characteristics, and severity of diarrhea in cancer patients in clinical practice. An observational, longitudinal, and prospective study of cancer outpatients treated with targeted OAAs was carried out in a tertiary hospital. Targed OAAs analyzed were anaplastic lymphoma kinase inhibitors, BCR-ABL inhibitors, cyclin-dependent kinase inhibitors, epidermal growth factor receptor inhibitors, mTOR inhibitors, poly (ADP-ribose) polymerase inhibitors, and vascular endothelial growth factor receptor inhibitors. Patients were given a data collection form to record daily the number, severity (CTCAE version 5.0), and characteristics of stools during the first 30 days of treatment with OAAs. Multivariate analysis was performed to identify risk factors associated with the incidence of diarrhea. We analyzed 240 patients, of whom 28.7% experienced diarrhea (25.4% grades 1-2 and 3.3% grades 3-4). Patients treated with EGFR and VEGFR inhibitors had a higher incidence of diarrhea. The multivariate analysis revealed that taking the OAA with food was associated with a lower risk of diarrhea (OR = 0.404 [0.205-0.956], p = 0.038). More than a third of patients in treatment with OAAs presented diarrhea (any grade), and 22.1% of stools were semi-liquid/liquid. In multivariate analysis, taking the OAA on an empty stomach was associated with a statistically significant increase in the incidence of diarrhea.
Sections du résumé
BACKGROUND
BACKGROUND
Diarrhea is one of the most frequent class adverse events associated with targeted oral antineoplastic agents (OAAs). Our objective was to analyze the incidence, characteristics, and severity of diarrhea in cancer patients in clinical practice.
METHODS
METHODS
An observational, longitudinal, and prospective study of cancer outpatients treated with targeted OAAs was carried out in a tertiary hospital. Targed OAAs analyzed were anaplastic lymphoma kinase inhibitors, BCR-ABL inhibitors, cyclin-dependent kinase inhibitors, epidermal growth factor receptor inhibitors, mTOR inhibitors, poly (ADP-ribose) polymerase inhibitors, and vascular endothelial growth factor receptor inhibitors. Patients were given a data collection form to record daily the number, severity (CTCAE version 5.0), and characteristics of stools during the first 30 days of treatment with OAAs. Multivariate analysis was performed to identify risk factors associated with the incidence of diarrhea.
RESULTS
RESULTS
We analyzed 240 patients, of whom 28.7% experienced diarrhea (25.4% grades 1-2 and 3.3% grades 3-4). Patients treated with EGFR and VEGFR inhibitors had a higher incidence of diarrhea. The multivariate analysis revealed that taking the OAA with food was associated with a lower risk of diarrhea (OR = 0.404 [0.205-0.956], p = 0.038).
CONCLUSIONS
CONCLUSIONS
More than a third of patients in treatment with OAAs presented diarrhea (any grade), and 22.1% of stools were semi-liquid/liquid. In multivariate analysis, taking the OAA on an empty stomach was associated with a statistically significant increase in the incidence of diarrhea.
Identifiants
pubmed: 33506273
doi: 10.1007/s00520-021-06016-z
pii: 10.1007/s00520-021-06016-z
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4673-4681Références
IMS Institute for Healthcare Informatics (2016) Global oncology trend report. A review of 2015 and outlook to 2020
Escudero-Vilaplana V, Revuelta-Herrero JL, Collado-Borrell R, Marzal-Alfaro B, Gimenez-Manzorro A, Herranz-Alonso A, Sanjurjo-Saez M (2019) Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice. Expert Opin Drug Saf 18(9):861–868
doi: 10.1080/14740338.2019.1641197
Ota K, Takeuchi T, Kojima Y, Harada S, Ozaki H, Sugawara N, Hirata Y, Yamaguchi T, Terazawa T, Kakimoto K, Kii T, Goto M, Higuchi K (2019) Fluorepyrimmide-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea. Scand J Gastroenterol 54(2):227–232
doi: 10.1080/00365521.2019.1575466
Pessi MA, Zilembo N, Haspinger ER, Molino L, di Cosimo S, Garassino M, Ripamonti CI (2014) Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol Hematol 90(2):165–179
doi: 10.1016/j.critrevonc.2013.11.008
Rugo HS, Di Palma JA, Tripathy D et al (2019) The characterization, management and future considerations of ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat 175(1):5–15
doi: 10.1007/s10549-018-05102-x
Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhea during cancer chemotherapy. Lancet Oncol 15(10):e477–e460
doi: 10.1016/S1470-2045(14)70006-3
Tarricone R, Abu Koush D, Nyanzi-Wakholi B, Medina-Lara A (2016) A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Crit Rev Oncol Hematol 99:37–48
doi: 10.1016/j.critrevonc.2015.12.012
Forde C (2017) Systemic anti-cancer therapy-induced diarrhea. Br J Hosp Med (Lond) 78(9):C135–C139
doi: 10.12968/hmed.2017.78.9.C135
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Bethesda, Md. U.S. Department of Health and Human Services, National Institutes of Health, 2017. National Cancer Institute
Richardson G, Dobish R (2007) Chemotherapy induced diarrhea. J Oncol Pharm Pract 13(4):181–189
doi: 10.1177/1078155207077335
Aw DC, Tan EH, Chin TM et al (2018) Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol 14(1):23–31
doi: 10.1111/ajco.12687
Davila M, Bresalier RS (2008) Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 5(12):682–696
doi: 10.1038/ncpgasthep1277
Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, di Bartolomeo M (2014) Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol 78(6):1228–1237
doi: 10.1111/bcp.12449
Barcenas CH, Hurvitz SA, Palma JAD et al (2020) Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 31(9):1223–1230
doi: 10.1016/j.annonc.2020.05.012
Xu C, Ravva P, Dang JS, Laurent J, Adessi C, McIntyre C, Meneses-Lorente G, Mercier F (2018) A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel. Cancer Chemother Pharmacol 82(3):395–406
doi: 10.1007/s00280-018-3621-9
Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J (2019) Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Support Care Cancer 27(3):1029–1039
doi: 10.1007/s00520-018-4392-x
Chan A, Delaloge S, Holmes FA, ExteNET Study Group et al (2016) Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17(3):367–377
doi: 10.1016/S1470-2045(15)00551-3
Johnston SRD, Harbeck N, Hegg R et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 20:JCO2002514
Leboulleux S, Bastholt L, Krause T et al (2012) Vandetanib in locally advanced or metastatic differenciated thyroid cancer: a randomized, double-blind, phase 2 trial. Lancet Oncol 123(9):897–905
doi: 10.1016/S1470-2045(12)70335-2
European Public Assessment Reports. Amsterdam: European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/ema_group_types/ema_medicine [Accessed in July 2020]
Passaro A, Di Maio M, Del Signore E et al (2014) Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clin Lung Cancer 15(4):307–312
doi: 10.1016/j.cllc.2014.04.006
Dranitsaris G, Lacouture ME (2014) Development of precition tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capcitabine. Breast Cancer Res Treat 147(3):631–638
doi: 10.1007/s10549-014-3126-0
Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST (2013) The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea, vomiting, diarrhoea, oral mucositis andfatigue. Pharmacoeconomics 31:753–766
doi: 10.1007/s40273-013-0081-2
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Version 1.0. Bethesda, Md. U.S. Department of Health and Human Services, National Institutes of Health, 2017. National Cancer Institute
Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915
doi: 10.1200/JCO.2014.57.9334